UK Markets closed

How Johnson & Johnson became the sprawling healthcare giant it is today

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
FILE PHOTO: A first aid kit made by Johnson & Johnson for sale on a store shelf in Westminster
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Carl O'Donnell

(Reuters) - Johnson & Johnson plans to spin off its consumer health division that sells Listerine and Baby Powder to focus on pharmaceuticals and medical devices in the biggest shake-up in the U.S. company's 135-year history.

Here is how J&J got to where it is today.


Robert Wood Johnson partners with brothers James Wood Johnson and Edward Mead Johnson to found Johnson & Johnson in 1886. It originally focused on ready-to-use sterile surgical dressings.


J&J begins producing Johnson’s Baby Powder.


In response to a global flu pandemic, J&J begins selling a mask designed to limit the spread of the airborne viral illness.


J&J invents Band-Aid and begins marketing it in 1921.


J&J completes its initial public offering and becomes a publicly traded company. It had annual sales of around $95 million at the time, compared to more than $80 billion in 2020.


J&J acquires Tylenol maker McNeil Laboratories.


J&J acquires Janssen Pharmaceuticals, which now makes ADHD drug Concerta and J&J’s COVID-19 vaccine.


The first lawsuit alleging that J&J’s Baby Powder contains cancer-causing asbestos is filed against J&J. Since then, J&J has faced thousands of lawsuits and billions of liabilities and has ceased distributing Baby Powder in the United States and Canada.


J&J acquires Centocor Biotech Inc, maker of Remicade for Crohn's disease, and renames it Janssen Biotech.


Johnson and Johnson acquires orthopedic device maker Synthes for nearly $20 billion to expand its medical product offerings.


J&J acquires Actelion for $30 billion, adding heart disease medicines such as Tracleer to its portfolio.


J&J begins developing a COVID-19 vaccine. It received authorization to begin administering its COVID-19 shot the following year.


(Reporting by Carl O'Donnell, Editing by Nick Zieminski)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting